<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8748462</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">35013326</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">8748462</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">268</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1038/s41531-021-00268-6</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical features of Parkinson’s disease patients and healthy controls.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical features of Parkinson’s disease patients and healthy controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>HC</th><th>Candidates for DBS</th><th>Non-candidates</th><th><italic>p</italic>: Candidates for DBS vs HC</th><th><italic>p</italic>: Non-candidates vs HC</th><th><italic>p</italic>: Candidates for DBS vs Non-candidates</th><th><italic>p</italic>: for linear trend, Candidates for DBS</th><th><italic>p</italic>: for linear trend, Non-candidates</th><th><italic>p</italic>: for differential trend between PD groups</th></tr></thead><tbody><tr><td><italic>N</italic></td><td>60</td><td>19</td><td>41</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Age at MRI [years]</td><td>61.79 ± 8.98 (46.14–77.72)</td><td>61.09 ± 7.32 (48.86–73.59)</td><td>61.96 ± 6.38 (49.09–82.95)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Sex [Men/women]</td><td>29 (48.33)/31 (51.67)</td><td>11 (57.9)/8 (42.1)</td><td>25 (61)/16 (39)</td><td>0.32</td><td>0.15</td><td>0.52</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Education [years]</td><td>13.52 ± 2.57 (8.00–16.00)</td><td>11.21 ± 3.06 (4–16)</td><td>12.34 ± 2.31 (8–17)</td><td>0.003</td><td>0.01</td><td>0.35</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Handedness [right/left/both]</td><td>46 (92) 4 (8) 0 (0)</td><td>18 (94.7) 1 (5.3) 0 (0)</td><td>36 (87.8) 4 (9.8) 1 (2.4)</td><td>0.58</td><td>0.50</td><td>0.64</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Age at onset [years]</td><td>–</td><td>52.05 ± 7.94 (42.0–64.0)</td><td>54.63 ± 6.45 (43.0–71.0)</td><td>–</td><td>–</td><td>0.19</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Disease duration [years]</td><td>–</td><td>8.94 ± 5.55 (4.28–23.93)</td><td>7.42 ± 3.65 (4.00–16.86)</td><td>–</td><td>–</td><td>0.24</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Family history [No/yes]</td><td>–</td><td>16 (84.2) 3 (15.8)</td><td>34 (82.9) 7 (17.1)</td><td>–</td><td>–</td><td>0.61</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Side of onset [Right/left/both]</td><td>–</td><td>12 (63.2) / 7 (36.8) / 0 (0)</td><td>25 (61.0) / 15 (36.6) / 1 (2.4)</td><td>–</td><td>–</td><td>0.79</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Hoehn &amp; Yahr</td><td>–</td><td>2.32 ± 0.74 (1–3)</td><td>1.94 ± 0.60 (1–3)</td><td>–</td><td>–</td><td>0.19</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.85</td></tr><tr><td>UPDRS total</td><td>–</td><td>65.00 ± 17.59 (28–90)</td><td>49.66 ± 17.35 (15–79)</td><td>–</td><td>–</td><td>0.002</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.06</td></tr><tr><td>UPDRS I total</td><td>–</td><td>3.84 ± 3.97 (0–12)</td><td>3.27 ± 2.99 (0–12)</td><td>–</td><td>–</td><td>0.54</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.16</td></tr><tr><td>UPDRS II total</td><td>–</td><td>14.21 ± 4.66 (3–21)</td><td>10.39 ± 4.49 (1–20)</td><td>–</td><td>–</td><td>0.004</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.07</td></tr><tr><td>UPDRS III T</td><td>–</td><td>43.68 ± 14.36 (14–62)</td><td>34.71 ± 13.34 (12–55)</td><td>–</td><td>–</td><td>0.02</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.67</td></tr><tr><td>UPDRS IV Total</td><td>–</td><td>3.26 ± 2.51 (0–9)</td><td>1.29 ± 1.69 (0–6)</td><td>–</td><td>–</td><td>0.01</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.04</td></tr><tr><td>Levodopa equivalent dose [mg]</td><td>–</td><td>882.63 ± 398.59 (0–1530)</td><td>679.15 ± 322.42 (0–1140)</td><td>–</td><td>–</td><td>0.07</td><td>&lt;0.001</td><td>&lt;0.001</td><td>1.00</td></tr></tbody></table><table-wrap-foot><p>Values are reported as mean ± standard deviation (range) or absolute and percentage frequency (%) for continuous and categorical variables, respectively. Differences between Parkinson’s disease patients and healthy controls and between Parkinson’s disease groups at baseline were assessed using ANOVA models (for continuous demographic and general clinical variables) and Chi-square test (for all categorical variables). Test for linear trend was estimated in both Parkinson’s disease groups and group-by-time interaction was assessed to evaluate longitudinal between-group differences. <italic>P</italic> values were adjusted for multiple comparisons at <italic>p</italic> &lt; 0.05.</p><p><italic>DBS</italic> deep brain stimulation, <italic>Candidates for DBS</italic> patients eligible for DBS, <italic>HC</italic> healthy controls, <italic>Non-candidates</italic> patients not eligible for DBS, <italic>PD</italic> Parkinson’s disease, <italic>UPDRS</italic> Unified Parkinson’s disease rating scale.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical features of Parkinson’s disease patients and healthy controls.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>HC</th><th>Candidates for DBS</th><th>Non-candidates</th><th>p: Candidates for DBS vs HC</th><th>p: Non-candidates vs HC</th><th>p: Candidates for DBS vs Non-candidates</th><th>p: for linear trend, Candidates for DBS</th><th>p: for linear trend, Non-candidates</th><th>p: for differential trend between PD groups</th></tr></thead><tbody><tr><td>N</td><td>60</td><td>19</td><td>41</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Age at MRI [years]</td><td>61.79 ± 8.98 (46.14–77.72)</td><td>61.09 ± 7.32 (48.86–73.59)</td><td>61.96 ± 6.38 (49.09–82.95)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Sex [Men/women]</td><td>29 (48.33)/31 (51.67)</td><td>11 (57.9)/8 (42.1)</td><td>25 (61)/16 (39)</td><td>0.32</td><td>0.15</td><td>0.52</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Education [years]</td><td>13.52 ± 2.57 (8.00–16.00)</td><td>11.21 ± 3.06 (4–16)</td><td>12.34 ± 2.31 (8–17)</td><td>0.003</td><td>0.01</td><td>0.35</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Handedness [right/left/both]</td><td>46 (92) 4 (8) 0 (0)</td><td>18 (94.7) 1 (5.3) 0 (0)</td><td>36 (87.8) 4 (9.8) 1 (2.4)</td><td>0.58</td><td>0.50</td><td>0.64</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Age at onset [years]</td><td>–</td><td>52.05 ± 7.94 (42.0–64.0)</td><td>54.63 ± 6.45 (43.0–71.0)</td><td>–</td><td>–</td><td>0.19</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Disease duration [years]</td><td>–</td><td>8.94 ± 5.55 (4.28–23.93)</td><td>7.42 ± 3.65 (4.00–16.86)</td><td>–</td><td>–</td><td>0.24</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Family history [No/yes]</td><td>–</td><td>16 (84.2) 3 (15.8)</td><td>34 (82.9) 7 (17.1)</td><td>–</td><td>–</td><td>0.61</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Side of onset [Right/left/both]</td><td>–</td><td>12 (63.2) / 7 (36.8) / 0 (0)</td><td>25 (61.0) / 15 (36.6) / 1 (2.4)</td><td>–</td><td>–</td><td>0.79</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Hoehn &amp; Yahr</td><td>–</td><td>2.32 ± 0.74 (1–3)</td><td>1.94 ± 0.60 (1–3)</td><td>–</td><td>–</td><td>0.19</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.85</td></tr><tr><td>UPDRS total</td><td>–</td><td>65.00 ± 17.59 (28–90)</td><td>49.66 ± 17.35 (15–79)</td><td>–</td><td>–</td><td>0.002</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.06</td></tr><tr><td>UPDRS I total</td><td>–</td><td>3.84 ± 3.97 (0–12)</td><td>3.27 ± 2.99 (0–12)</td><td>–</td><td>–</td><td>0.54</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.16</td></tr><tr><td>UPDRS II total</td><td>–</td><td>14.21 ± 4.66 (3–21)</td><td>10.39 ± 4.49 (1–20)</td><td>–</td><td>–</td><td>0.004</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.07</td></tr><tr><td>UPDRS III T</td><td>–</td><td>43.68 ± 14.36 (14–62)</td><td>34.71 ± 13.34 (12–55)</td><td>–</td><td>–</td><td>0.02</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.67</td></tr><tr><td>UPDRS IV Total</td><td>–</td><td>3.26 ± 2.51 (0–9)</td><td>1.29 ± 1.69 (0–6)</td><td>–</td><td>–</td><td>0.01</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.04</td></tr><tr><td>Levodopa equivalent dose [mg]</td><td>–</td><td>882.63 ± 398.59 (0–1530)</td><td>679.15 ± 322.42 (0–1140)</td><td>–</td><td>–</td><td>0.07</td><td>&lt;0.001</td><td>&lt;0.001</td><td>1.00</td></tr></tbody></table></div>Values are reported as mean ± standard deviation (range) or absolute and percentage frequency (%) for continuous and categorical variables, respectively. Differences between Parkinson’s disease patients and healthy controls and between Parkinson’s disease groups at baseline were assessed using ANOVA models (for continuous demographic and general clinical variables) and Chi-square test (for all categorical variables). Test for linear trend was estimated in both Parkinson’s disease groups and group-by-time interaction was assessed to evaluate longitudinal between-group differences. P values were adjusted for multiple comparisons at p &lt; 0.05.DBS deep brain stimulation, Candidates for DBS patients eligible for DBS, HC healthy controls, Non-candidates patients not eligible for DBS, PD Parkinson’s disease, UPDRS Unified Parkinson’s disease rating scale.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Graph analysis properties of brain global and lobar networks in healthy controls and PD patient groups.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>Graph analysis properties of brain global and lobar networks in healthy controls and PD patient groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Regions</th><th>Graph analysis properties</th><th>HC</th><th>Candidates for DBS</th><th>Non-candidates</th><th><italic>p</italic>: Non-candidates vs HC</th><th><italic>p</italic>: Candidates for DBS vs HC</th><th><italic>p</italic>: Candidates for DBS vs Non-candidates</th><th><italic>p</italic>: for linear trend, Candidates for DBS</th><th><italic>p</italic>: for linear trend, Non-candidates</th><th><italic>p</italic>: for differential trend between PD groups</th></tr></thead><tbody><tr><td>Global</td><td>Nodal strength</td><td>4.03 ± 0.94 (2.48–7.57)</td><td>4.36 ± 0.85 (2.68–6.40)</td><td>4.12 ± 0.86 (2.86–7.28)</td><td>1.00</td><td>0.68</td><td>0.94</td><td>0.002</td><td>0.15</td><td>0.003</td></tr><tr><td/><td>Path length</td><td>6.71 ± 1.12 (4.06–9.98)</td><td>6.32 ± 1.00 (4.33–8.35)</td><td>6.66 ± 0.97 (4.12–8.44)</td><td>1.00</td><td>0.68</td><td>0.75</td><td>0.01</td><td>1.00</td><td>0.64</td></tr><tr><td/><td>Local efficiency</td><td>0.26 ± 0.05 (0.16–0.46)</td><td>0.30 ± 0.05 (0.20–0.43)</td><td>0.28 ± 0.05 (0.20–0.42)</td><td>0.87</td><td>0.11</td><td>0.66</td><td>0.004</td><td>0.15</td><td>&lt;0.001</td></tr><tr><td/><td>Clustering coefficient</td><td>0.16 ± 0.03 (0.09–0.30)</td><td>0.18 ± 0.03 (0.11–0.26)</td><td>0.17 ± 0.03 (0.11–0.27)</td><td>0.94</td><td>0.19</td><td>0.92</td><td>0.01</td><td>0.14</td><td>0.001</td></tr><tr><td>Sensorimotor</td><td>Nodal strength</td><td>5.87 ± 1.67 (2.53–10.35)</td><td>6.05 ± 1.66 (2.51–11.57)</td><td>6.19 ± 1.95 (2.59–14.33)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.03</td><td>1.00</td><td>0.17</td></tr><tr><td/><td>Path length</td><td>5.97 ± 1.23 (3.40–9.53)</td><td>6.33 ± 2.94 (3.59–9.30)</td><td>6.04 ± 1.07 (3.01–8.77)</td><td>1.00</td><td>0.70</td><td>1.00</td><td>1.00</td><td>0.90</td><td>1.00</td></tr><tr><td/><td>Local efficiency</td><td>0.31 ± 0.08 (0.16–0.51)</td><td>0.33 ± 0.09 (0.15–0.53)</td><td>0.35 ± 0.11 (0.14–0.70)</td><td>0.16</td><td>0.99</td><td>1.00</td><td>0.052</td><td>0.76</td><td>0.34</td></tr><tr><td/><td>Clustering coefficient</td><td>0.18 ± 0.05 (0.09–0.30)</td><td>0.19 ± 0.06 (0.07–0.38)</td><td>0.20 ± 0.08 (0.07–0.50)</td><td>0.12</td><td>1.00</td><td>1.00</td><td>0.27</td><td>0.69</td><td>0.78</td></tr><tr><td>Frontal insular</td><td>Nodal strength</td><td>3.90 ± 0.97 (2.35–7.49)</td><td>3.96 ± 0.88 (2.22–6.37)</td><td>3.87 ± 0.89 (2.34–7.34)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.03</td><td>0.16</td><td>0.01</td></tr><tr><td/><td>Path length</td><td>6.64 ± 1.14 (4.00–9.73)</td><td>6.41 ± 1.07 (4.67–10.30)</td><td>6.59 ± 0.99 (4.02–9.84)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.01</td><td>1.00</td><td>0.11</td></tr><tr><td/><td>Local efficiency</td><td>0.26 ± 0.05 (0.17–0.45)</td><td>0.27 ± 0.05 (0.17–0.39)</td><td>0.26 ± 0.05 (0.17–0.46)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.01</td><td>0.08</td><td>0.003</td></tr><tr><td/><td>Clustering coefficient</td><td>0.17 ± 0.04 (0.10–0.30)</td><td>0.17 ± 0.04 (0.10–0.26)</td><td>0.16 ± 0.04 (0.11–0.31)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.02</td><td>0.07</td><td>0.004</td></tr><tr><td>Temporal</td><td>Nodal strength</td><td>2.94 ± 0.77 (1.63–5.65)</td><td>3.40 ± 0.73 (1.61–4.49)</td><td>3.05 ± 0.80 (1.72–5.92)</td><td>1.00</td><td>0.09</td><td>0.33</td><td>&lt;0.001</td><td>0.39</td><td>0.001</td></tr><tr><td/><td>Path length</td><td>7.26 ± 1.28 (4.51–10.60)</td><td>6.47 ± 1.06 (5.49–10.94)</td><td>7.11 ± 1.13 (4.40–10.04)</td><td>1.00</td><td>0.06</td><td>0.18</td><td>0.001</td><td>1.00</td><td>0.03</td></tr><tr><td/><td>Local Efficiency</td><td>0.27 ± 0.06 (0.16–0.46)</td><td>0.30 ± 0.06 (0.15–0.43)</td><td>0.28 ± 0.07 (0.16–0.65)</td><td>0.65</td><td>0.06</td><td>0.59</td><td>0.01</td><td>0.31</td><td>0.002</td></tr><tr><td/><td>Clustering coefficient</td><td>0.18 ± 0.05 (0.10–0.34)</td><td>0.20 ± 0.04 (0.10–0.27)</td><td>0.18 ± 0.06 (0.09–0.44)</td><td>0.94</td><td>0.16</td><td>0.81</td><td>0.01</td><td>0.25</td><td>0.002</td></tr><tr><td>Parietal</td><td>Nodal strength</td><td>5.56 ± 1.54 (3.12–10.97)</td><td>5.80 ± 1.58 (3.31–8.86)</td><td>5.61 ± 1.48 (3.15–10.65)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.09</td><td>0.37</td><td>0.08</td></tr><tr><td/><td>Path length</td><td>5.82 ± 1.01 (3.42–8.53)</td><td>5.70 ± 0.95 (3.69–7.79)</td><td>5.85 ± 1.00 (3.37–8.30)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.07</td><td>1.00</td><td>0.32</td></tr><tr><td/><td>Local efficiency</td><td>0.29 ± 0.07 (0.19–0.53)</td><td>0.30 ± 0.07 (0.19–0.48)</td><td>0.29 ± 0.06 (0.17–0.50)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.10</td><td>0.45</td><td>0.06</td></tr><tr><td/><td>Clustering coefficient</td><td>0.16 ± 0.04 (0.09–0.31)</td><td>0.17 ± 0.46 (0.10–0.27)</td><td>0.16 ± 0.04 (0.09–0.30)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.24</td><td>0.54</td><td>0.14</td></tr><tr><td>Occipital</td><td>Nodal strength</td><td>3.99 ± 1.24 (1.76–8.23)</td><td>5.31 ± 1.59 (2.66–8.37)</td><td>4.48 ± 1.36 (2.23–8.94)</td><td>0.38</td><td>0.001</td><td>0.06</td><td>0.13</td><td>0.19</td><td>0.048</td></tr><tr><td/><td>Path length</td><td>6.67 ± 1.38 (3.84–11.55)</td><td>5.84 ± 0.97 (4.38–7.90)</td><td>6.38 ± 1.12 (3.70–9.15)</td><td>1.00</td><td>0.06</td><td>0.33</td><td>0.003</td><td>1.00</td><td>0.04</td></tr><tr><td/><td>Local efficiency</td><td>0.33 ± 0.09 (0.15–0.65)</td><td>0.42 ± 0.11 (0.27–0.65)</td><td>0.36 ± 0.10 (0.18–0.73)</td><td>0.48</td><td>0.001</td><td>0.06</td><td>0.67</td><td>0.24</td><td>0.04</td></tr><tr><td/><td>Clustering coefficient</td><td>0.21 ± 0.07 (0.09–0.44)</td><td>0.27 ± 0.09 (0.15–0.45)</td><td>0.23 ± 0.07 (0.10–0.50)</td><td>0.55</td><td>0.01</td><td>0.11</td><td>0.14</td><td>0.41</td><td>0.09</td></tr><tr><td>Basal ganglia</td><td>Nodal strength</td><td>4.13 ± 1.14 (2.10–8.61)</td><td>4.25 ± 1.37 (2.21–7.42)</td><td>4.02 ± 1.23 (2.24–8.90)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.04</td><td>0.32</td></tr><tr><td/><td>Path length</td><td>7.00 ± 1.19 (4.12–10.08)</td><td>6.69 ± 1.09 (4.74–10.83)</td><td>7.11 ± 1.27 (4.27–9.64)</td><td>1.00</td><td>1.00</td><td>0.60</td><td>0.54</td><td>0.76</td><td>0.27</td></tr><tr><td/><td>Local efficiency</td><td>0.20 ± 0.04 (0.12–0.34)</td><td>0.20 ± 0.05 (0.13–0.41)</td><td>0.21 ± 0.06 (0.11–0.45)</td><td>1.00</td><td>0.60</td><td>1.00</td><td>1.00</td><td>0.03</td><td>0.15</td></tr><tr><td/><td>Clustering coefficient</td><td>0.10 ± 0.03 (0.05–0.17)</td><td>0.10 ± 0.03 (0.06–0.21)</td><td>0.10 ± 0.03 (0.05–0.22)</td><td>1.00</td><td>0.97</td><td>1.00</td><td>1.00</td><td>0.02</td><td>0.20</td></tr></tbody></table><table-wrap-foot><p>Values are reported as mean ± standard deviation (range). Global and lobar metrics were compared between groups using age- and sex-adjusted ANOVA models, followed by post-hoc pairwise comparisons, Bonferroni-corrected for multiple comparisons (<italic>p</italic> &lt; 0.05). Test for linear trend was estimated in both PD-DBS and PD-noDBS groups, and group-by-time interaction was assessed to evaluate longitudinal between-group differences. Such models were adjusted for age, sex, LEDD at baseline, LEDD changes, and individual follow-up duration. <italic>P</italic> values were adjusted for multiple comparisons (<italic>p</italic> &lt; 0.05).</p><p><italic>DBS</italic> deep brain stimulation, <italic>Candidates for DBS</italic> patients eligible for DBS, <italic>Non-candidates</italic> patients not eligible for DBS, <italic>HC</italic> healthy controls, <italic>PD</italic> Parkinson’s disease.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Graph analysis properties of brain global and lobar networks in healthy controls and PD patient groups.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Regions</th><th>Graph analysis properties</th><th>HC</th><th>Candidates for DBS</th><th>Non-candidates</th><th>p: Non-candidates vs HC</th><th>p: Candidates for DBS vs HC</th><th>p: Candidates for DBS vs Non-candidates</th><th>p: for linear trend, Candidates for DBS</th><th>p: for linear trend, Non-candidates</th><th>p: for differential trend between PD groups</th></tr></thead><tbody><tr><td>Global</td><td>Nodal strength</td><td>4.03 ± 0.94 (2.48–7.57)</td><td>4.36 ± 0.85 (2.68–6.40)</td><td>4.12 ± 0.86 (2.86–7.28)</td><td>1.00</td><td>0.68</td><td>0.94</td><td>0.002</td><td>0.15</td><td>0.003</td></tr><tr><td/><td>Path length</td><td>6.71 ± 1.12 (4.06–9.98)</td><td>6.32 ± 1.00 (4.33–8.35)</td><td>6.66 ± 0.97 (4.12–8.44)</td><td>1.00</td><td>0.68</td><td>0.75</td><td>0.01</td><td>1.00</td><td>0.64</td></tr><tr><td/><td>Local efficiency</td><td>0.26 ± 0.05 (0.16–0.46)</td><td>0.30 ± 0.05 (0.20–0.43)</td><td>0.28 ± 0.05 (0.20–0.42)</td><td>0.87</td><td>0.11</td><td>0.66</td><td>0.004</td><td>0.15</td><td>&lt;0.001</td></tr><tr><td/><td>Clustering coefficient</td><td>0.16 ± 0.03 (0.09–0.30)</td><td>0.18 ± 0.03 (0.11–0.26)</td><td>0.17 ± 0.03 (0.11–0.27)</td><td>0.94</td><td>0.19</td><td>0.92</td><td>0.01</td><td>0.14</td><td>0.001</td></tr><tr><td>Sensorimotor</td><td>Nodal strength</td><td>5.87 ± 1.67 (2.53–10.35)</td><td>6.05 ± 1.66 (2.51–11.57)</td><td>6.19 ± 1.95 (2.59–14.33)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.03</td><td>1.00</td><td>0.17</td></tr><tr><td/><td>Path length</td><td>5.97 ± 1.23 (3.40–9.53)</td><td>6.33 ± 2.94 (3.59–9.30)</td><td>6.04 ± 1.07 (3.01–8.77)</td><td>1.00</td><td>0.70</td><td>1.00</td><td>1.00</td><td>0.90</td><td>1.00</td></tr><tr><td/><td>Local efficiency</td><td>0.31 ± 0.08 (0.16–0.51)</td><td>0.33 ± 0.09 (0.15–0.53)</td><td>0.35 ± 0.11 (0.14–0.70)</td><td>0.16</td><td>0.99</td><td>1.00</td><td>0.052</td><td>0.76</td><td>0.34</td></tr><tr><td/><td>Clustering coefficient</td><td>0.18 ± 0.05 (0.09–0.30)</td><td>0.19 ± 0.06 (0.07–0.38)</td><td>0.20 ± 0.08 (0.07–0.50)</td><td>0.12</td><td>1.00</td><td>1.00</td><td>0.27</td><td>0.69</td><td>0.78</td></tr><tr><td>Frontal insular</td><td>Nodal strength</td><td>3.90 ± 0.97 (2.35–7.49)</td><td>3.96 ± 0.88 (2.22–6.37)</td><td>3.87 ± 0.89 (2.34–7.34)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.03</td><td>0.16</td><td>0.01</td></tr><tr><td/><td>Path length</td><td>6.64 ± 1.14 (4.00–9.73)</td><td>6.41 ± 1.07 (4.67–10.30)</td><td>6.59 ± 0.99 (4.02–9.84)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.01</td><td>1.00</td><td>0.11</td></tr><tr><td/><td>Local efficiency</td><td>0.26 ± 0.05 (0.17–0.45)</td><td>0.27 ± 0.05 (0.17–0.39)</td><td>0.26 ± 0.05 (0.17–0.46)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.01</td><td>0.08</td><td>0.003</td></tr><tr><td/><td>Clustering coefficient</td><td>0.17 ± 0.04 (0.10–0.30)</td><td>0.17 ± 0.04 (0.10–0.26)</td><td>0.16 ± 0.04 (0.11–0.31)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.02</td><td>0.07</td><td>0.004</td></tr><tr><td>Temporal</td><td>Nodal strength</td><td>2.94 ± 0.77 (1.63–5.65)</td><td>3.40 ± 0.73 (1.61–4.49)</td><td>3.05 ± 0.80 (1.72–5.92)</td><td>1.00</td><td>0.09</td><td>0.33</td><td>&lt;0.001</td><td>0.39</td><td>0.001</td></tr><tr><td/><td>Path length</td><td>7.26 ± 1.28 (4.51–10.60)</td><td>6.47 ± 1.06 (5.49–10.94)</td><td>7.11 ± 1.13 (4.40–10.04)</td><td>1.00</td><td>0.06</td><td>0.18</td><td>0.001</td><td>1.00</td><td>0.03</td></tr><tr><td/><td>Local Efficiency</td><td>0.27 ± 0.06 (0.16–0.46)</td><td>0.30 ± 0.06 (0.15–0.43)</td><td>0.28 ± 0.07 (0.16–0.65)</td><td>0.65</td><td>0.06</td><td>0.59</td><td>0.01</td><td>0.31</td><td>0.002</td></tr><tr><td/><td>Clustering coefficient</td><td>0.18 ± 0.05 (0.10–0.34)</td><td>0.20 ± 0.04 (0.10–0.27)</td><td>0.18 ± 0.06 (0.09–0.44)</td><td>0.94</td><td>0.16</td><td>0.81</td><td>0.01</td><td>0.25</td><td>0.002</td></tr><tr><td>Parietal</td><td>Nodal strength</td><td>5.56 ± 1.54 (3.12–10.97)</td><td>5.80 ± 1.58 (3.31–8.86)</td><td>5.61 ± 1.48 (3.15–10.65)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.09</td><td>0.37</td><td>0.08</td></tr><tr><td/><td>Path length</td><td>5.82 ± 1.01 (3.42–8.53)</td><td>5.70 ± 0.95 (3.69–7.79)</td><td>5.85 ± 1.00 (3.37–8.30)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.07</td><td>1.00</td><td>0.32</td></tr><tr><td/><td>Local efficiency</td><td>0.29 ± 0.07 (0.19–0.53)</td><td>0.30 ± 0.07 (0.19–0.48)</td><td>0.29 ± 0.06 (0.17–0.50)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.10</td><td>0.45</td><td>0.06</td></tr><tr><td/><td>Clustering coefficient</td><td>0.16 ± 0.04 (0.09–0.31)</td><td>0.17 ± 0.46 (0.10–0.27)</td><td>0.16 ± 0.04 (0.09–0.30)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.24</td><td>0.54</td><td>0.14</td></tr><tr><td>Occipital</td><td>Nodal strength</td><td>3.99 ± 1.24 (1.76–8.23)</td><td>5.31 ± 1.59 (2.66–8.37)</td><td>4.48 ± 1.36 (2.23–8.94)</td><td>0.38</td><td>0.001</td><td>0.06</td><td>0.13</td><td>0.19</td><td>0.048</td></tr><tr><td/><td>Path length</td><td>6.67 ± 1.38 (3.84–11.55)</td><td>5.84 ± 0.97 (4.38–7.90)</td><td>6.38 ± 1.12 (3.70–9.15)</td><td>1.00</td><td>0.06</td><td>0.33</td><td>0.003</td><td>1.00</td><td>0.04</td></tr><tr><td/><td>Local efficiency</td><td>0.33 ± 0.09 (0.15–0.65)</td><td>0.42 ± 0.11 (0.27–0.65)</td><td>0.36 ± 0.10 (0.18–0.73)</td><td>0.48</td><td>0.001</td><td>0.06</td><td>0.67</td><td>0.24</td><td>0.04</td></tr><tr><td/><td>Clustering coefficient</td><td>0.21 ± 0.07 (0.09–0.44)</td><td>0.27 ± 0.09 (0.15–0.45)</td><td>0.23 ± 0.07 (0.10–0.50)</td><td>0.55</td><td>0.01</td><td>0.11</td><td>0.14</td><td>0.41</td><td>0.09</td></tr><tr><td>Basal ganglia</td><td>Nodal strength</td><td>4.13 ± 1.14 (2.10–8.61)</td><td>4.25 ± 1.37 (2.21–7.42)</td><td>4.02 ± 1.23 (2.24–8.90)</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td><td>0.04</td><td>0.32</td></tr><tr><td/><td>Path length</td><td>7.00 ± 1.19 (4.12–10.08)</td><td>6.69 ± 1.09 (4.74–10.83)</td><td>7.11 ± 1.27 (4.27–9.64)</td><td>1.00</td><td>1.00</td><td>0.60</td><td>0.54</td><td>0.76</td><td>0.27</td></tr><tr><td/><td>Local efficiency</td><td>0.20 ± 0.04 (0.12–0.34)</td><td>0.20 ± 0.05 (0.13–0.41)</td><td>0.21 ± 0.06 (0.11–0.45)</td><td>1.00</td><td>0.60</td><td>1.00</td><td>1.00</td><td>0.03</td><td>0.15</td></tr><tr><td/><td>Clustering coefficient</td><td>0.10 ± 0.03 (0.05–0.17)</td><td>0.10 ± 0.03 (0.06–0.21)</td><td>0.10 ± 0.03 (0.05–0.22)</td><td>1.00</td><td>0.97</td><td>1.00</td><td>1.00</td><td>0.02</td><td>0.20</td></tr></tbody></table></div>Values are reported as mean ± standard deviation (range). Global and lobar metrics were compared between groups using age- and sex-adjusted ANOVA models, followed by post-hoc pairwise comparisons, Bonferroni-corrected for multiple comparisons (p &lt; 0.05). Test for linear trend was estimated in both PD-DBS and PD-noDBS groups, and group-by-time interaction was assessed to evaluate longitudinal between-group differences. Such models were adjusted for age, sex, LEDD at baseline, LEDD changes, and individual follow-up duration. P values were adjusted for multiple comparisons (p &lt; 0.05).DBS deep brain stimulation, Candidates for DBS patients eligible for DBS, Non-candidates patients not eligible for DBS, HC healthy controls, PD Parkinson’s disease.</transformed-table></extracted-table></extracted-tables-set>